Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.

GRP-60367 is the first small molecule rabies virus (RABV) entry inhibitor, which has nanomolar effect on some RABV strains.Grp-60367 inhibits the entry of a subset of the RABV strain.Grp-60367 showed the specificity and effective anti-RABV activity of the scaffold. In the dose-response analysis, the EC50s range from 2 to 52 nM in different host cell lines.

VU625 (VU007625) is a selective and potent AeKir1 inhibitor (IC50: 96.8 nM) that acts as a mosquito killer and inhibits AeKir1-mediated currents.